Sector News

AZ spends $200M to expand US biologics site

November 24, 2014
Life sciences
AstraZeneca has announced plans to expand its US biologics manufacturing centre in Frederick, Maryland, spending more than $200 million to increase production in support of its “maturing pipeline”.
 
The company says the investment will help it keep pace “with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline”. The expansion, which is expected to be complete in mid-2017, will add 40,000 square feet of manufacturing, laboratory and administrative space and bring 300 new jobs to the site; the company currently employs over 3,000 people in Maryland.
 
Andrew Skibo, regional head of biologics supply for AstraZeneca, noted that the firm’s MedImmune unit “has a robust pipeline of more than 120 biologics, including more than 30 in clinical development. The expansion of our Frederick facility will support the progression of drug candidates across our core therapeutic areas”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach